Peroxisome proliferator-activated receptor γ (PPARγ) and Wnt play different roles in bone homeostasis. Thiazolidinediones are PPARγ agonists that cause bone mineral density loss. This study investigated the relationship between PPARγ and Wnt/β-catenin signaling in mouse osteoblastic MC3T3-E1 cells.
Methods
MC3T3-E1 cells were treated with either pioglitazone (Pio) or rosiglitazone (Rosi), thiazolidinediones, for 24 hours at 10 to 40-μM concentrations. Recombinant mouse Wnt3a protein (50 ng/mL) for 6 hours was also used to treat the 20-μM Pio and Rosi pretreated cells. Cell proliferation was measured by MTT, and apoptosis with flow cytometry using annexin V/propidium iodide staining; reverse transcriptase–polymerase chain reaction measured mRNA expression levels of LRP5/6 (low-density lipoprotein–related protein 5/6), glycogen synthase kinase 3β (GSK3β), TCF7L2 (transcription factor 7–like 2), PPARγ, and cyclin D1, and Western blots detected β-catenin and p-GSK3β proteins.
Results
Pioglitazone and Rosi decreased MC3T3-E1 cell viability by 28.07% and 18.14% at 20 μM, respectively (P < 0.05). Apoptosis increased compared with controls (7.21%), after 20-μM treatment with Pio or Rosi, to 10.45% and 12.10%, respectively (P < 0.05). Both Pio and Rosi decreased β-catenin protein levels and increased p-GSK3β, but the LRP5/6, GSK3β, and TCF7L2 mRNA levels were constant. Upon activation of the Wnt pathway by mouse Wnt3a protein, β-catenin and p-GSK3β protein levels were reversed, accompanied with increased proliferation, but apoptosis remained high.
Conclusions
Activation of PPARγ in osteoblasts accompanied Wnt signaling suppression. Activation of Wnt signaling alleviated the PPARγ proliferation decreases but not the apoptosis increases. The thiazolidinedione PPARγ agonists act in part through inhibition of the Wnt signaling pathway, showing there is a relationship between PPARγ and Wnt signaling.
ChenL, YangG.PPARs integrate the mammalian clock and energy metabolism. PPAR Res. 2014; 2014: 653017.
2.
RzoncaSO, SuvaLJ, GaddyD, . Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004; 145: 401–406.
3.
LehrkeM, LazarMA.The many faces of PPARgamma. Cell. 2005; 123: 993–999.
4.
MonsalveFA, PyarasaniRD, Delgado-LopezF, . Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013; 2013: 549627.
5.
KahnSE, HaffnerSM, HeiseMA, . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427–2443.
6.
InvestigatorsDT, GersteinHC, YusufS, . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368: 1096–1105.
7.
GimbleJM, RobinsonCE, WuX, . Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996; 50: 1087–1094.
8.
JeonMJ, KimJA, KwonSH, . Activation of peroxisome proliferator-activated receptor-gamma inhibits the runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem. 2003; 278: 23270–23277.
9.
ChanBY, GartlandA, WilsonPJ, . PPAR agonists modulate human osteoclast formation and activity in vitro. Bone. 2007; 40: 149–159.
10.
KhanE, Abu-AmerY.Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J Lab Clin Med. 2003; 142: 29–34.
11.
PeiL, TontonozP.Fat's loss is bone's gain. J Clin Invest. 2004; 113: 805–806.
Lecka-CzernikB, Ackert-BicknellC, AdamoML, . Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology. 2007; 148: 903–911.
14.
AkuneT, OhbaS, KamekuraS, . PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004; 113: 846–855.
15.
MabilleauG, ChappardD, BasleMF.Cellular and molecular effects of thiazolidinediones on bone cells: a review. Int J Biochem Mol Biol. 2011; 2: 240–246.
16.
AliAA, WeinsteinRS, StewartSA, . Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005; 146: 1226–1235.
17.
GreyA, BollandM, GambleG, . The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007; 92: 1305–1310.
18.
SchwartzAV, SellmeyerDE, VittinghoffE, . Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006; 91: 3349–3354.
19.
GlintborgD, AndersenM, HagenC, . Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2008; 93: 1696–1701.
20.
KahnSE, ZinmanB, LachinJM, . Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT). Diabetes care. 2008; 31: 845–851.
21.
MonamiM, CresciB, ColombiniA, . Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care. 2008; 31: 199–203.
22.
OgawaS, UranoT, HosoiT, . Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun. 1999; 260: 122–126.
23.
RheeEJ, OhKW, LeeWY, . The effects of c161–>t polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol. 2005; 192: 1087–1093.
24.
KielDP, FerrariS, CupplesLA.Polymorphism in the PPARg influence bone density in humans. J Bone Miner Res. 2005; 20: S234.
KrishnanV, BryantHU, MacdougaldOA.Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116: 1202–1209.
32.
BodinePV, ZhaoW, KharodeYP, . The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004; 18: 1222–1237.
33.
HuH, HiltonMJ, TuX, . Sequential roles of hedgehog and Wnt signaling in osteoblast development. Development. 2005; 132: 49–60.
34.
HillTP, SpaterD, TaketoMM, . Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005; 8: 727–738.
35.
GlassDA2nd, BialekP, AhnJD, . Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8: 751–764.
36.
LiuJ, FarmerSR.Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem. 2004; 279: 45020–45027.
37.
SharmaC, PradeepA, WongL, . Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem. 2004; 279: 35583–35594.
38.
MulhollandDJ, DedharS, CoetzeeGA, . Interaction of nuclear receptors with the Wnt/beta-catenin/tcf signaling axis: Wnt you like to know?Endocr Rev. 2005; 26: 898–915.
39.
AlmeidaM, HanL, BellidoT, . Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin–dependent and –independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/Akt. J Biol Chem. 2005; 280: 41342–41351.
40.
ChungYS, BaylinkDJ, SrivastavaAK, . Effects of secreted frizzled-related protein 3 on osteoblasts in vitro. J Bone Miner Res. 2004; 19: 1395–1402.
OkamuraM, KudoH, WakabayashiK, . Coup-TFII acts downstream of Wnt/beta-catenin signal to silence PPARgamma gene expression and repress adipogenesis. Proc Natl Acad Sci U S A. 2009; 106: 5819–5824.
44.
LiuB, YuHM, HsuW.Craniosynostosis caused by axin2 deficiency is mediated through distinct functions of beta-catenin in proliferation and differentiation. Dev Biol. 2007; 301: 298–308.
45.
MirandoAJ, MaruyamaT, FuJ, . Beta-catenin/cyclin d1 mediated development of suture mesenchyme in calvarial morphogenesis. BMC Dev Biol. 2010; 10: 116.
46.
AlmeidaM, AmbroginiE, HanL, . Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem. 2009; 284: 27438–27448.
47.
MoldesM, ZuoY, MorrisonRF, . Peroxisome-proliferator–activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis. Biochem J. 2003; 376: 607–613.
48.
TakadaI, KouzmenkoAP, KatoS.Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol. 2009; 5: 442–447.
